ArticleJournal of clinical laboratory analysis2009
CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
Article in Journal of clinical laboratory analysis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Association of the CXCL12 rs1801157 Polymorphism with Breast Cancer Risk: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis.Hematological oncology · 2017Pooled it
- The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants.Scientific reports · 2016Pooled it
- CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Pooled it
- CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis.Molecular biology reports · 2012Pooled it
- Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China.Frontiers in oncology · 2024Article
- Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.Molecular biology reports · 2022Article
- CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.Molecular biology reports · 2018Article
- Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan andPeerJ · 2017Article
- Article
- Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes.Molecular and cellular pediatrics · 2016Article
- Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues.Oncology letters · 2016Article
- CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.Cellular and molecular life sciences : CMLS · 2015Review
- Article
- CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.Clinical and experimental medicine · 2013Article
- CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL).Molecular biology reports · 2013Article
- Perturbation of invadolysin disrupts cell migration in zebrafish (Danio rerio).Experimental cell research · 2013Article
- Common sequence variants in chemokine-related genes and risk of breast cancer in post-menopausal women.International journal of molecular epidemiology and genetics · 2013Article
- Association between SDF1-3'A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases.Molecular biology reports · 2012Article
- A model of GAG/MIP-2/CXCR2 interfaces and its functional effects.Biochemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines and their receptors regulate the trafficking of immune cells during their development, inflammation, and tissue repair. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3'A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using a restriction enzyme HpaII cleavage. No significant difference was observed in genotype distribution between breast cancer patients (GG: 57.3%; GA: 39.8%; AA: 2.9%) and healthy female controls (GG: 62.9%; GA: 33%; AA: 4.1%) nor between HL patients (GG: 61.1%; GA:27.8%; AA: 11.1%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%), whereas a significant difference was observed in genotype distribution between NHL patients (GG: 51.4%; GA: 47.1%; AA: 1.5%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%). Further studies will be necessary to elucidate the cancer chemokine network. However, this study suggests that CXCL12 rs1801157 polymorphism may have important implications in the pathogenesis of NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.